Table 3.

Glucose and lipid metabolism dynamics in patients with schizophrenia during a 6-week treatment depending on the presence or absence of MetS [Me (Q1; Q3)].

Time-point for the assessment	Patients with MetS (n = 43)	p-value	Patients without MetS (n = 71)	p-value
Glucose metabolism
Glucose
At hospitalization, mmol/l	5.15 [4.60; 5.60]	0.345	4.95 [4.75; 5.10]	<0.001*
After a 6-week treatment, mmol/l	5.20 [4.70; 5.90]		5.35 [4.80; 5.60]
Insulin
At hospitalization, µIU/ml	3.75 [2.02; 8.59]	0.482	0.65 [0.12; 2.79]	0.079
After a 6-week treatment, µIU/ml	5.54 [2.21; 9. 75]		1.50 [0.58; 4.57]
HOMA-IR
At hospitalization	0.17 [0. 28; 0.43]	0.053	0.17 [0. 28; 0.43]	0.023*
After a 6-week treatment	0.32 [0.12; 0. 94]		0.32 [0.12; 0. 94]
Lipid metabolism
Total cholesterol
At hospitalization, mmol/l	4.63 [4.09; 5.10]	0.021*	4.64 [3.83; 5.15]	0.083
After a 6-week treatment, mmol/l	4.79 [3.92; 5.49]		4.63 [3.98; 5.21]
Triglycerides
At hospitalization, mmol/l	2.05 [1.75; 1.55]	0.073	1.05 [0.71; 1.25]	<0.001*
After a 6-week treatment, mmol/l	2.45 [1.85; 2.72]		1.52 [1.22; 2.00]
High-density lipoproteins
At hospitalization, mmol/l	1.00 [0.80; 1.10]	0.706	1.23 [1.05; 1.40]	0.336
After a 6-week treatment, mmol/l	0.85 [0.60-1.35]		1.00 [0.80-1.40]
Low-density lipoproteins
At hospitalization, mmol/l	2.80 [1.95; 3.20]	0.242	2.90 [2.12; 3.65]	0.466
After a 6-week treatment, mmol/l	2.57 [1.65; 3.37]		2.72 [2.34; 3.40]
Very low-density lipoproteins
At hospitalization, mmol/l	0.93 [0.80; 1.16]	0.073	0.48 [0.32; 0.57]	<0.001*
After a 6-week treatment, mmol/l	1.1 [0.84; 1.24]		0.69 [0.56; 0.91]
Atherogenic index
At hospitalization	3.74 [2.94; 5. 51]	0.029*	2.82 [1.92; 3.54]	0.042*
After a 6-week treatment	3.99 [2.32; 7.65]		3.69 [2.31; 5.39]

*p < 0.05—statistically significant difference. HOMA-IR: homeostasis model assessment of insulin resistance. Comparisons between groups were performed using the Wilcoxon signed-rank test.